Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 52-week randomized double-blind study of QVM149 versus QMF149 in uncontrolled severe asthma
MOH_2017-03-13_000235Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of indacaterol acetate + glycopyrronium bromide + mometasone furoate in asthma (5 arms), sponsored by Novartis. Primary endpoints: Efficacy based on lung function and Safety. Started Mar 2016; status: completed.
02
Drugs
indacaterol acetate + glycopyrronium bromide + mometasone furoate
03
Conditions
asthma
Beyond the preview
Go deeper on MOH_2017-03-13_000235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-13_000235.